South & Central America Breast Cancer Therapeutics Market Forecast to 2030
South & Central America Breast Cancer Therapeutics Market Forecast to 2030 – Regional Analysis – by Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Use of Personalized Medicine Fuels, the South & Central America Breast Cancer Therapeutics Market
Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patients cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancers growth by analyzing a patients tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patients tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.
South & Central America Breast Cancer Therapeutics Market Overview
The breast cancer therapeutics market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to have a major share in this region. It is also projected to grow at the highest growth rate. Increasing prevalence of breast cancer, aging population, and rise in per capita health care spending are among the factors that are expected to propel the breast cancer therapeutics market rapidly.
The increasing prevalence of breast cancer in Brazil drives the demand for breast cancer therapeutics. Breast cancer is the most prevalent malignancy in women in Brazil, according to Nature Publications. According to the Brazilian National Cancer Institute (INCA), approximately 66,200 new cases of breast cancer in women are identified in Brazil annually, translating to an age-standardized incidence rate of 43.74/100,000 women.
Improving healthcare infrastructure and access to advanced medical technologies in Brazil also drive the market. The government has been investing in expanding healthcare facilities and improving access to healthcare services, including breast cancer screening and treatment. This has led to early detection of breast cancer cases and increased the demand for therapeutics. Thus, the growing prevalence of breast cancer, improving healthcare infrastructure, and rising breast cancer awareness are key factors driving the breast cancer therapeutics market in Brazil.
South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Breast Cancer Therapeutics Market Segmentation
The South & Central America breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.
Based on drug therapy, the South & Central America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the South & Central America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.
By distribution channel, the South & Central America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.
Based on country, the South & Central America breast cancer therapeutics market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil dominated the South & Central America breast cancer therapeutics market in 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the South & Central America breast cancer therapeutics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the South & Central America breast cancer therapeutics market was valued at US$ 1,530.71 million in 2022 and is expected to reach US$ 2,953.26 million by 2030, registering a CAGR of 8.6% from 2022 to 2030. Increased support from government and private organizations and growing burden of breast cancer are among the critical factors attributed to the South & Central America breast cancer therapeutics market expansion.
Governments of various countries recognize the importance of addressing breast cancer and are implementing policies to improve access to effective treatments. Many governments and private organizations have increased funding for research and development in breast cancer therapeutics, resulting in the development of innovative drugs and therapies. In 2022, through the “Mulheres Amigas – Temporada Amazônia” program, Daiichi Sankyo Brasil (DSBR) started offering free breast cancer screenings to women in Brazil’s Amazon region. The increased investment in research has allowed pharmaceutical companies to explore new treatment options and develop highly targeted and effective therapies for breast cancer patients.
Several government bodies across the world are also taking steps to improve access to these treatments by implementing reimbursement policies and healthcare initiatives that cover the cost of breast cancer therapeutics for patients. This means that more patients can afford these treatments and have access to the latest advancements in breast cancer therapeutics. The increased government support has also created a favorable market environment for healthcare providers. With more funding and resources available, healthcare providers are able to offer their patients a wider range of treatment options. This improves patient outcomes and allows healthcare providers to stay competitive in the market. Overall, the increased support from governments and private organizations for breast cancer therapeutics has driven innovation, leading to new and improved treatments. It has also improved access to these treatments, benefiting more patients. This presents a significant opportunity for the South & Central America breast cancer therapeutics market growth as pharmaceutical companies and healthcare providers continue to invest in research and development activities and expand their offerings to meet the growing demand.
On the contrary, high cost of diagnosis and treatment hampers the growth South & Central America breast cancer therapeutics market.
Based on drug therapy, the South & Central America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 59.9% share of the South & Central America breast cancer therapeutics market in 2022, amassing US$ 917.24 million. It is projected to garner US$ 1,894.39 million by 2030 to expand at 9.5% CAGR during 2022–2030. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the South & Central America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 68.5% share of the South & Central America breast cancer therapeutics market in 2022, amassing US$ 1,049.27 million. It is projected to garner US$ 2,128.62 million by 2030 to expand at 9.2% CAGR during 2022–2030.
By distribution channel, the South & Central America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 73.6% share of South & Central America breast cancer therapeutics market in 2022, amassing US$ 1,126.35 million. It is projected to garner US$ 2,252.06 million by 2030 to expand at 9.0% CAGR during 2022–2030.
Based on country, the South & Central America breast cancer therapeutics market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil held 61.5% share of South & Central America breast cancer therapeutics market in 2022, amassing US$ 941.15 million. It is projected to garner US$ 1,914.39 million by 2030 to expand at 9.3% CAGR during 2022–2030.
Key players operating in the South & Central America breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc, among others.
In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreement’s terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally. In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in South & Central America breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Breast Cancer Therapeutics Market – Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market – South & Central America Market Analysis
5.1 South & Central America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 – 2030
6. South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Drug Therapy
6.1 Overview
6.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 South & Central America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 South & Central America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Breast Cancer Type
7.1 Overview
7.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Breast Cancer Therapeutics Market -Country Analysis
9.1 South & Central America Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 South & Central America Breast Cancer Therapeutics Market, Breakdown, by Country -Revenue (2022) (US$ Million)
9.1.3 South & Central America Breast Cancer Therapeutics Market, By Countries, 2022 and 2030 (%)
9.1.3.1 Brazil
9.1.3.1.1 Brazil Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 Brazil: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 Brazil: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 Brazil: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 Brazil: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 Brazil: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Argentina
9.1.3.2.1 Argentina Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Argentina: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Argentina: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Argentina: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Argentina: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Argentina: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 Rest of South & Central America
9.1.3.3.1 Rest of South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 Rest of South & Central America: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 Rest of South & Central America: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 Rest of South & Central America: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 Rest of South & Central America: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 Rest of South & Central America: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. South & Central America Breast Cancer Therapeutics Market Segmentation
Table 2. South & Central America Breast Cancer Therapeutics Market, by Targeted Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 3. South & Central America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 4. Brazil Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 5. Brazil Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 6. Brazil Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 7. Brazil Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. Brazil Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 9. Argentina Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 10. Argentina Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 11. Argentina Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 12. Argentina Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. Argentina Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. Rest of South & Central America Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 15. Rest of South & Central America Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 16. Rest of South & Central America Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 17. Rest of South & Central America Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. Rest of South & Central America Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 20. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 21. Glossary of Terms, Breast Cancer Therapeutics Market
LIST OF FIGURES
Figure 1. South & Central America Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. South & Central America Breast Cancer Therapeutics Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. South & Central America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 – 2030
Figure 5. South & Central America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. South & Central America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. South & Central America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: South & Central America Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. South & Central America Breast Cancer Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 19. South & Central America Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. Brazil Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Argentina Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Rest of South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Growth Strategies in Breast Cancer Therapeutics Market
The List of Companies – South & Central America Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.